<DOC>
	<DOCNO>NCT00269906</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy abciximab , anti-platelet therapy , versus placebo patient unstable angina respond standard medical therapy eligible coronary angioplasty .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Safety Abciximab , Anti-Platelet Therapy , Patients With Unstable Angina Not Responding Standard Medical Therapy Who Are Eligible Coronary Angioplasty</brief_title>
	<detailed_description>This randomize , placebo-controlled study evaluate safety efficacy abciximab , anti-platelet therapy , patient unstable angina respond standard medical therapy eligible coronary angioplasty . The primary outcome study include follow within 30 day : number death cause , myocardial infarction number recurrent ischemic event require urgent intervention ( coronary artery bypass surgery , repeat coronary angioplasty , coronary stent placement , intra-aortic balloon pump ) . Please see attached result . Patients treat abciximab match placebo .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Patients refractory angina evidence least one episode ischemia ( chest pain and/or STT change ) despite bed rest least 2 hour treatment oral intravenous nitrate intravenous heparin , persistent newly develop negative Twaves occur continue least 2 hour treatment oral intravenous nitrate intravenous heparin Having clinical sign symptom angina rest minimal exertion dynamic STsegment and/or Twave change Having episode chest pain within 48 hour prior start study agent administration Having culprit lesion single native coronary vessel suitable angioplasty qualify angiogram Patients recent myocardial infarction , unless CK return less twice upper limit normal Having feature ongoing ischemia would require immediate intervention , percutaneous transluminal coronary angioplasty ( PTCA ) within past 24 hour Having unprotected occlusion main leave coronary artery &gt; 50 % , culprit lesion locate venous arterial bypass graft , recent bleed condition associate increase bleed risk Receiving concurrent administration oral anticoagulant time study entry , administration intravenous dextran ( prior plan use angioplasty ) , plan administration thrombolytic agent prior angioplasty Having persistent hypertension admission despite treatment , platelet count le 100,000 per millimeter cubed</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Angina , unstable</keyword>
	<keyword>Angioplasty , transluminal , percutaneous coronary</keyword>
	<keyword>Abciximab</keyword>
</DOC>